Yüklüyor......
Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone that blocks androgen biosynthesis, is approved for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with prednisone or prednisolone 5 mg twice daily. This review evaluates the basis f...
Kaydedildi:
| Yayımlandı: | Oncologist |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AlphaMed Press
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4257741/ https://ncbi.nlm.nih.gov/pubmed/25361624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0167 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|